Ajinomoto to buy gene therapy CDMO Forge Biologics in $620M all-cash deal
CDMO and biotech Forge Biologics will be acquired by Ajinomoto in an all-cash deal worth $620 million, a move that will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.